CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors Melbourne, Australia: CSL has confirmed all Australian on-site employees, contractors and visitors will be required to be...

CSL confirms there was a positive COVID-19 case at its Broadmeadows manufacturing facility last week. All employees and contractors who were present at the same time as the confirmed case have...

$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2021: Australia’s top biomedical researchers are invited to apply for one of two CSL Centenary...

New Patent Box policy will benefit domestic commercialisation of medical research Melbourne, Australia: CSL welcomes the Federal Government’s Budget commitment to introduce a Patent Box that...

Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies Melbourne, Australia: CSL welcomes the Government’s plan to further develop onshore mRNA...

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein...

Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million doses a week - these volumes have been produced for a number...

Four Australian Research Programs to be Fast-Tracked in Partnership with CSL Melbourne, Australia: Four Australian medical researcher programs have been awarded a CSL Research Acceleration...

CSL remains committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines. We will continue our focused and...

CSL continues to provide medicines to patients around the world. Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide...